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Abstract: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an ultra-rare disease
for which there are currently no validated outcome measures for assessing therapeutic intervention
efficacy. The aim of this study was to identify a plasma and/or serum microRNA (miRNA) biomarker
panel for MNGIE. Sixty-five patients and 65 age and sex matched healthy controls were recruited
and assigned to one of four study phases: (i) discovery for sample size determination; (ii) candidate
screening; (iii) candidate validation; and (iv) verifying the performance of the validated miRNA panel
in four patients treated with erythrocyte-encapsulated thymidine phosphorylase (EE-TP), an enzyme
replacement under development for MNGIE. Quantitative PCR (qPCR) was used to profile miRNAs
in serum and/or plasma samples collected for the discovery, validation and performance phases, and
next generation sequencing (NGS) analysis was applied to serum samples assigned to the candidate
screening phase. Forty-one differentially expressed candidate miRNAs were identified in the sera of
patients (p < 0.05, log2 fold change > 1). The validation cohort revealed that of those, 27 miRNAs
were upregulated in plasma and three miRNAs were upregulated in sera (p < 0.05). Through binary
logistic regression analyses, five plasma miRNAs (miR-192-5p, miR-193a-5p, miR-194-5p, miR-215-5p
and miR-34a-5p) and three serum miRNAs (miR-192-5p, miR-194-5p and miR-34a-5p) were shown
to robustly distinguish MNGIE from healthy controls. Reduced longitudinal miRNA expression of
miR-34a-5p was observed in all four patients treated with EE-TP and coincided with biochemical and
clinical improvements. We recommend the inclusion of the plasma exploratory miRNA biomarker
panel in future clinical trials of investigational therapies for MNGIE; it may have prognostic value
for assessing clinical status.
Keywords: MNGIE; Mitochondrial neurogastrointestinal encephalomyopathy; miRNA; biomarker;
mitochondrial disease; thymidine phosphorylase; erythrocyte encapsulated thymidine phosphory-
lase; outcome measures; miR-34a-5p
1. Introduction
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE, Online Mendelian
inheritance in Man #603041, Genome Database accession #9835128) is an ultra-rare autoso-
mal recessive disease caused by mutations in TYMP, the nuclear gene which encodes for the
enzyme, thymidine phosphorylase. The resulting enzyme deficiency leads to plasma and
tissue accumulations of thymidine and 2′-deoxyuridine, which create imbalances within
the mitochondrial deoxynucleotide pools that, in turn, produce multiple mitochondrial
deoxyribonucleic acid (mtDNA) deletions, depletion and site-specific point mutations,
ultimately causing mitochondrial dysfunction [1–5]. MNGIE manifests clinically as severe
gastrointestinal dysmotility, sensorimotor peripheral neuropathy, chronic progressive ex-
ternal ophthalmoplegia, severe muscle weakness and progressive leukoencephalopathy.
The disease is relentlessly progressive, with patients usually dying from a combination of
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gastrointestinal and nutritional failure as well as neuro muscular disability at an average
age of 37.6 years [6].
Although there is currently no universally established treatment to prevent or reverse
the inexorable fatal clinical deterioration in patients with MNGIE, a number of experi-
mental therapeutic approaches have been investigated over the past two decades [7–19].
Unique challenges face the translation of candidate therapeutics into approved treatments
for rare diseases, and MNGIE is no exception. The small patient population and phenotypic
heterogeneity of MNGIE, together with the small number of reported cases, an incomplete
knowledge of the disease’s natural history and the absence of prospective clinical studies
and validated outcome measures to quantitate disease progression have all contributed
to the difficulty in selecting clinical trial endpoints for this disorder. Current clinical trial
protocols for MNGIE have selected a range of primary and secondary clinical outcome
measures that will enable the capture of clinical effect in a condition for which there is
phenotypic variability (e.g., gastrointestinal and/or neuropathic), through the use of in-
struments that are not disease specific but have been shown to correlate significantly with
both generic and disease targeted long-standing (legacy) instruments.
To expedite the development of drugs for rare diseases, the regulatory agencies have
endorsed the need for flexibility in the review process and may consider approving a
therapy based on a surrogate endpoint, such as a biomarker that is predictive of clinical
benefit [20]. The definition of a biomarker is a biological characteristic that can be objec-
tively measured and evaluated as a signal of normal biological or pathological processes
and thus has the potential to improve diagnosis, predict disease manifestation and monitor
responses to therapeutic intervention. Whereas clinical outcome measures directly assess
how an individual feel, functions or survives, biomarkers substitute for a clinical endpoint
and link a measurement to a prediction of the effect of the treatment on the clinical outcome
of interest. Biomarker endpoints have the advantage of reducing drug approval time com-
pared to the wait for the realisation of clinical endpoints, thereby expediating patient access
to therapeutic benefits. Indeed, biomarker endpoints, both validated and unvalidated, have
been used to support drug approvals through expedited pathways available for medicinal
products intended to treat seriously debilitating or life-threatening diseases [21].
MicroRNAs (miRNAs) are a class of endogenous non-coding ribonucleic acids (RNAs)
of 21–24 nucleotides in length that induce post-transcriptional gene silencing. In the ma-
jority of cases the miRNAs bind via complementary base-pairing with the 3′ untranslated
region (3′ UTR) of target messenger RNAs (mRNAs) to induce mRNA degradation or trans-
lation repression [22]. miRNAs can be found in virtually in all cellular compartments and
have been shown to exist in a stable state in most extracellular fluids through their binding
with argonuate proteins and encapsulation by extracellular vesicles [23]. A growing body
of evidence shows that miRNAs have unique expression profiles in the extracellular fluids
of patients with a range of diseases, compared to healthy individuals, and thus may have
clinical relevance as disease biomarkers [24–26].
The absence of validated outcome measures to quantitate MNGIE disease progression
and determine the effectiveness of potential therapies led us to investigate whether a panel
of miRNAs could serve as a potential biomarker for MNGIE. Our previously reported
feasibility study showed that compared to age and sex matched healthy controls, there was
significant dysregulation in a number of miRNAs in the sera of patients with MNGIE [27].
To further explore the clinical applicability of circulating miRNAs as biomarkers of MNGIE,
we report here an expanded miRNA expression profiling study comprising four phases,
with each phase recruiting different cohorts of patients and healthy controls.
2. Results
2.1. Study Design
The study was conducted in four phases according to the study design depicted in
Figure 1. The aim of the discovery phase was to permit a power calculation for sample size
determination for subsequent phases. In the second, candidate screening phase samples
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were analysed by next generation sequencing (NGS). The aim of this phase was to iden-
tify suitable candidate miRNAs and normalisers for verification by real-time quantitative
polymerase chain reaction (RT-qPCR) in the validation phase. An additional aim of the
validation phase was to determine whether the type of blood biofluid (plasma or serum)
had an effect on the miRNA measurement. Finally, the responses of the validated miR-
NAs to the compassionate treatment of patients with erythrocyte-encapsulated thymidine
phosphorylase (EE-TP), an enzyme replacement therapy under clinical development for
MNGIE, were assessed in the performance phase of the study.
Figure 1. Study design showing the aims of the four study phases, the patient cohort numbers, the
sample types analysed and the microRNA (miRNA) analysis platform employed for each phase.
2.2. Study Population
Age and sex matched healthy controls were recruited into each study cohort. The dis-
covery cohort consisted of five males and five females per participant group (healthy
control and patient), with an average participant age of 31 ± 6.1 years (mean ± SD).
To examine the possible effects of disease progression on the miRNA expression profile,
the candidate screening cohort was subdivided into three age range groups: ≤19 years
(3 males, 2 females; mean age 13± 4.2 years), 20–29 years (3 males, 5 females; mean age 23.3
± 2.6 years) and ≥30 years (4 males, 3 females; mean age 33.9 ± 3.2 years). The validation
cohort consisted of both serum and plasma samples to ascertain whether the two biofluids
provided similar miRNA profiles. The participant demographics for the serum samples
were: ≤19 years (4 males, 2 females; mean age 11.3 ± 4.6 years), 20–29 years (3 males, 2
females; mean age 22.6 ± 0.6 years) and ≥ 30 years (5 males, 1 female; mean age 39.0 ±
11.1 years); and for the plasma samples: ≤19 years (0 male, 4 females; mean age 17.0 ± 1.4
years), 20–29 years (4 males, 5 females; mean age 24.4 ± 2.6 years) and ≥30 years (3 males,
2 females; mean age 36.2 ± 4.4 years). The performance cohort consisted of serum samples
which had been collected longitudinally from four patients with MNGIE who had received
treatment with EE-TP.
2.3. Discovery Phase
2.3.1. Data Quality Control (QC)
Box and whisker plots comparing distributions revealed a normalised dataset with
no identified sample outliers; see Figure A1. A comparison of sample distributions on
a pairwise basis, with different regression fits, revealed no outliers. Some lower tails in
distributions were observed in some pairwise comparisons via locally estimated scatterplot
smoothing (LOESS, see Section 4.5.1), but this was most likely due to biological variability
(data- not shown).
Unsupervised clustering analysis revealed a natural separation between healthy con-
trol and patient serum samples, and showed that the miRNA profile amongst the control
group was similar, whereas it exhibited greater variability in MNGIE samples, based on
pairwise Euclidean distances; see Figure 2. This was also evident via principal component
analysis (PCA), where variability in controls was mostly confined to principal component
1 (PC1) (15.66% explained variation), whilst variability in MNGIE occurred along both PC1
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and PC2 (9.37% variation). No PC segregated MNGIE from controls in a conclusive fashion.
Of the PCs accounting for large (>5%) amounts of variation, PC2 appeared to segregate
both groups along an axis at, roughly, eigenvalue 0.
Figure 2. Heatmap of Euclidian distances between healthy control and mitochondrial neurogastroin-
testinal encephalomyopathy (MNGIE) disease serum miRNA expression profiles (n=20). The colour
level is proportional to the value of the dissimilarity, ranging from blue (similarity) to red, which
corresponds to the highest value of Euclidean distance and thus dissimilarity. The miRNA profiles
were more dissimilar between the MNGIE samples.
2.3.2. Differentially Expressed miRNAs
A total of 27 miRNAs were differentially expressed between healthy control and
MNGIE serum samples when applying the threshold of p ≤0.05 (Benjamini–Hochberg
adjusted) and an absolute fold-change > ± 2; see Table 1. These included 14 upregulated
and 13 downregulated miRNAs; see Figure 3.
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Table 1. Discovery study: fold changes and p-values of miRNAs differentially expressed in the sera from healthy controls and patients with MNGIE.
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Figure 3. Box plots with scatter-plot overlays of serum miRNA expression in patients with MNGIE and healthy controls. Fourteen miRNAs (top two panels) were significantly upregulated
and thirteen miRNAs were significantly downregulated (bottom two panels) in patients with MNGIE compared to healthy controls. Boxes display interquartile ranges (25–75%) and error
bars indicate minimum and maximum values.
Int. J. Mol. Sci. 2021, 22, 3681 7 of 50
Supervised clustering of these differentially expressed miRNAs was able to segregate
healthy controls from MNGIE; see Figure 4. Based on the heatmap shading, the majority
of these miRNAs were either exclusively highly expressed in healthy control serum or
MNGIE disease serum. A few miRNAs, in addition to being highly expressed in controls,
were also highly expressed in 1 or 2 MNGIE samples (e.g., miR-409−3p). These were
assumed genuine biological effects in which the MNGIE patient sample in question may
be at a different stage of disease. This data strongly suggests that, serum miRNAs profiles
can segregate the healthy and disease groups.
Figure 4. Heatmap of differentially expressed miRNAs determined in the discovery study by
quantitative PCR (qPCR) in Scheme 27. statistically significantly differentially expressed miRNAs
passing the threshold of p ≤ 0.05 (Benjamini–Hochberg adjusted) and an absolute fold-change > ±2.
Based on the heatmap shading, the majority of the miRNAs were either exclusively highly expressed
in the healthy control serum or in the MNGIE disease serum. A box and whisker plot of miRNA
Z-scores is shown on the right-hand side of the heatmap.
A power analysis of the data at a 0.95 level of confidence and for a p-value of 0.05
revealed that 17 samples per group would be required to detect an effect in a follow-on
validation study.
2.4. Candidate Screening Phase
2.4.1. Descriptive Analysis of Sequencing Data
One patient sample (SP1) yielded a very low library, rendering it unfit for pooling
with the other libraries and was therefore removed from the downstream sequencing work.
All other samples passed the quality control criteria (see Table A1). Expression levels of
miR-103a-3p, miR-191-5p, miR-451a, miR-23a-3p and miR-30c-5p were within the expected
range for miRNAs in biofluids. The dCp (miR23a-miR451a) values were 5 or less, indicating
no haemolysis (Figure A2).
The QC spike-ins added during the RNA isolation procedure showed count corre-
lations (R2) between the samples in the range of 0.95–0.99, therefore demonstrating the
reproducibility of the NGS data. miRNA sequencing generated 745 million raw sequencing
reads with an average of 19.1 million raw reads/sample. Following Unique Molecu-
lar Index (UMI) correction, an average of 1.55 million reads were obtained per sample.
Each sample consisted of reads that were classified into the following categories: miRNA,
small RNA, predicted putative miRNA, genome-mapped, outmapped or high abundance
(e.g., ribosomal RNA, polyA, polyC, mitochondrial RNA) and unmapped (reads which did
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not align to the reference genome); see Table A2. Averaging the data from all 39 samples,
59.7% of the UMI-corrected reads were mappable; 26.4% were mapped to MiRBase20,
18.1% a small RNA database, and 12.6% were aligned to the GRCh37 reference genome, but
not to miRNA or small RNAs. In additional, 0.04% of the reads represent putative miRNAs
that mapped to the reference genome outside the miRNA locus and were predicted using
mirPara64 and miRbase; see Table A2. The Phred quality scores for all UMI-corrected reads,
both control and patient samples, were above 30% (>99.9% accuracy), representing a high
and uniform quality of reads. This refers to the mean Phred scores per read (per sequence
quality) and to Phred scores along all reads (per base quality); see Figures A3 and A4,
respectively. Read length distribution after filtering of the adapters is shown in Figure
A5. The majority of reads were 18–23 nucleotide bases in length, which corresponds to the
expected length of mature miRNAs. This data demonstrates a high technical performance
of miRNA sequencing and a good sample quality.
2.4.2. miRNA Expression
Following data mapping and counting to relevant entries in mirbase20 which contains
2578 mature miRNA sequences, a total of 1219 miRNAs were identified in the 39 libraries.
By employing tags per million mapped reads (TPM) as a unit of expression, 170 and 121 of
known miRNAs were expressed at ≥1TPM and ≥10TPM, respectively, in each of the 39
serum samples, and these were accepted for further analysis; see Figure A6. Due to the
discovery study revealing a greater variability in the miRNA profiles in serum samples
from MNGIE patients, compared to healthy controls, it was hypothesised that this was
related to the extent of disease progression. To investigate this further, we examined
the expression profiles of miRNA in samples collected from three different age ranges:
≤19, 20–29 and ≥30 years of age; these broadly corresponding to early, mid and late
disease progression status, respectively. To explore biological differences between these
sample groups, a PCA was firstly conducted on the top 50 miRNAs that showed the largest
variation across all samples. Figure 5 shows a clear division in the miRNA expression
profiles between the MNGIE and healthy control groups along PC2, but particularly in the
age group ranges 20–29 and ≥30 years, thereby demonstrating the similarity of samples
within the study groups.
Figure 5. Assessment of intergroup and intragroup variability: A principal component analysis plot
displaying all 39 samples in principal component 1 (PC1) and PC2, which describe 25.8% and 8.5% of
the variability, respectively, within the expression data set. PC analysis was applied to normalised
(TMM) and log-transformed count data. A clear division can be seen in the miRNA expression
profiles between the MNGIE and healthy control groups along PC2. Age group 1 = ≤19 years (n = 4
and 5 for patient and healthy control groups, respectively); age group 2 = 20–29 years (n = 8 for each
group); age group 3 = ≥30 years (n = 7 for each participant group).
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By examining the component loading it was shown that miR-122-5P separates healthy
from disease samples and was therefore the primary driver of this segregation; see Figure 6.
Figure 6. Component loadings for PCs 1–6 reveal that miR-122-5p is the dominant source of variation
along PC2, a PC along which healthy and disease samples are visually segregated. For each PC,
only miRNAs falling within the top 1% of the overall loadings range for each PC were plotted.
2.4.3. Differentially Expressed miRNA Profile
Of the 1219 known miRNAs identified in this screening study, a total of 80 miRNAs
were differentially expressed: 55 of these were upregulated in MNGIE compared to healthy
controls, and 25 were downregulated; see Table 2.
Supervised hierarchical clustering of the data showed that in general, the significantly
differentially expressed miRNAs are able to distinguish between MNGIE disease and
healthy control samples; see Figure 7.
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Table 2. Differentially expressed miRNAs detected by sequencing in sera from patients with MNGIE compared to sera of healthy controls, according to age range.
Age Range * miRNA ID MNGIE Mean TMM Healthy Control MeanTMM Log FC p-Value FDR
miRNAs over-expressed in MNGIE vs. healthy controls
≤19 hsa-miR-215-5p 183 6 4.60 <0.0001 0.0211
20–29 hsa-miR-451a 14,019 4301 1.70 <0.0001 0.0004
hsa-miR-32-5p 227 39 2.52 <0.0001 0.0028
hsa-miR-363-3p 315 99 1.66 <0.0001 0.0028
hsa-miR-501-3p 274 91 1.56 <0.0001 0.0028
hsa-miR-194-5p 588 203 1.53 <0.0001 0.0028
hsa-miR-502-3p 69 18 1.89 0.0001 0.0028
hsa-miR-4732-5p 1927 320 2.59 0.0001 0.0029
hsa-miR-214-3p 14 1 2.84 0.0001 0.0030
hsa-miR-210-3p 34 8 1.98 0.0001 0.0030
hsa-miR-107 866 236 1.88 0.0001 0.0030
hsa-miR-22-3p 1239 362 1.77 0.0001 0.0040
hsa-miR-34a-5p 82 21 1.93 0.0002 0.0060
hsa-miR-106b-5p 43 13 1.68 0.0002 0.0060
hsa-miR-942-5p 149 69 1.09 0.0002 0.0060
hsa-miR-192-5p 991 376 1.40 0.0003 0.0075
hsa-miR-486-5p 262,731 103,131 1.35 0.0004 0.0086
hsa-miR-130b-3p 108 33 1.69 0.0004 0.0089
hsa-miR-16-5p 360,834 151,980 1.25 0.0005 0.0099
hsa-miR-15a-5p 800 256 1.64 0.0006 0.0108
hsa-miR-660-5p 751 332 1.17 0.0006 0.0110
hsa-miR-1285-3p 7 0 4.77 0.0008 0.0121
hsa-miR-484 1831 647 1.50 0.0007 0.0121
hsa-miR-182-5p 1745 632 1.46 0.0008 0.0121
hsa-miR-378a-3p 247 121 1.02 0.0010 0.0146
hsa-miR-183-5p 1230 459 1.42 0.0017 0.0225
hsa-miR-1224-5p 83 19 2.16 0.0019 0.0237
hsa-miR-320a 9249 3080 1.59 0.0019 0.0237
hsa-miR-629-5p 618 261 1.24 0.0019 0.0237
hsa-miR-503-5p 55 23 1.23 0.0023 0.0258
hsa-miR-92a-3p 53,636 25,118 1.09 0.0023 0.0258
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Table 2. Cont.
Age Range * miRNA ID MNGIE Mean TMM Healthy Control MeanTMM Log FC p-Value FDR
hsa-miR-3613-5p 182 57 1.66 0.0028 0.0296
hsa-miR-483-5p 1689 579 1.54 0.0030 0.0296
hsa-miR-4467 13 1 3.15 0.0033 0.0323
hsa-miR-423-5p 82,538 33,034 1.32 0.0035 0.0330
hsa-miR-6805-5p 16 3 2.21 0.0047 0.0404
hsa-miR-450a-2-3p 4 0 2.50 0.0049 0.0408
hsa-miR-101-3p 1911 886 1.11 0.0051 0.0420
hsa-miR-1294 70 30 1.20 0.0053 0.0422
hsa-miR-15b-5p 1428 703 1.02 0.0053 0.0422
hsa-miR-1180-3p 232 98 1.24 0.0060 0.0452
hsa-miR-486-3p 225 102 1.13 0.0065 0.0460
hsa-miR-885-5p 60 13 2.15 0.0071 0.0494
≥30 hsa-miR-483-5p 2391 478 2.32 <0.0001 0.0031
hsa-miR-215-5p 142 37 1.97 0.0001 0.0034
hsa-miR-34a-5p 108 31 1.75 0.0001 0.0034
hsa-let-7b-3p 45 14 1.60 0.0001 0.0034
hsa-miR-192-5p 1150 487 1.24 0.0001 0.0043
hsa-miR-193b-3p 9 0 4.84 0.0001 0.0053
hsa-miR-193b-5p 199 51 1.96 0.0002 0.0053
hsa-miR-193a-5p 1001 409 1.29 0.0002 0.0054
hsa-miR-214-3p 27 5 2.56 0.0003 0.0084
hsa-miR-206 928 145 2.67 0.0004 0.0085
hsa-miR-125b-5p 2115 989 1.09 0.0003 0.0085
hsa-miR-194-5p 618 259 1.25 0.0006 0.0128
hsa-miR-122-5p 160,505 52,033 1.63 0.0007 0.0137
hsa-miR-10b-5p 1093 514 1.09 0.0007 0.0137
hsa-miR-885-3p 156 40 1.94 0.0010 0.0202
hsa-miR-874-3p 86 38 1.19 0.0020 0.0346
hsa-miR-4467 15 2 2.86 0.0026 0.0412
hsa-miR-423-5p 59,588 33,945 0.81 0.0028 0.0432
miRNAs under-expressed in MNGIE vs. healthy controls
20–29 hsa-miR-181c-3p 2 26 −3.09 <0.0001 0.0004
hsa-miR-1301-3p 66 172 −1.36 <0.0001 0.0028
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Table 2. Cont.
Age Range * miRNA ID MNGIE Mean TMM Healthy Control MeanTMM Log FC p-Value FDR
hsa-miR-142-3p 3476 7917 −1.19 0.0002 0.0050
hsa-miR-5193 0 7 −3.66 0.0002 0.0060
hsa-miR-744-5p 546 1169 −1.10 0.0005 0.0106
hsa-miR-582-3p 3 15 −2.32 0.0006 0.0108
hsa-miR-3168 0 6 −3.37 0.0008 0.0121
hsa-miR-151a-5p 84 182 −1.09 0.0013 0.0179
hsa-miR-873-5p 0 4 −3.85 0.0028 0.0296
hsa-miR-340-3p 3 12 −2.16 0.0037 0.0330
hsa-miR-7849-3p 1 6 −2.55 0.0044 0.0385
hsa-miR-4433b-5p 327 949 −1.54 0.0059 0.0450
hsa-miR-31-5p 2 11 −2.21 0.0061 0.0456
hsa-miR-6721-5p 10 32 −1.62 0.0065 0.0460
≥30 hsa-miR-487b-3p 11 64 −2.42 <0.0001 0.0005
hsa-miR-370-3p 55 235 −2.07 <0.0001 0.0013
hsa-miR-485-3p 114 492 −2.12 <0.0001 0.0013
hsa-miR-485-5p 28 87 −1.65 0.0001 0.0034
hsa-miR-412-5p 0 9 −3.57 0.0001 0.0051
hsa-miR-411-5p 7 41 −2.35 0.0002 0.0053
hsa-miR-6767-5p 0 6 −4.30 0.0004 0.0085
hsa-miR-362-5p 0 5 −4.15 0.0011 0.0203
hsa-miR-409-3p 626 1788 −1.51 0.0017 0.0307
hsa-miR-30d-3p 0 6 −2.91 0.0031 0.0458
hsa-miR-199a-5p 31 67 −1.02 0.0035 0.0498
* Sample size: ≤19, n = 4 for healthy control group, n = 5 for patient group; 20–29, n = 8 for both healthy control and patient groups; ≥30; n = 7 for healthy control and patient groups.
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Figure 7. Heatmap and hierarchical cluster analysis of the differentially expressed miRNAs between
MNGIE patients and healthy controls detected in the candidate screening study by next generation
sequencing (NGS). Supervised clustering was performed on the 80 statistically significantly differ-
entially expressed miRNAs passing the threshold of p ≤ 0.05 (Benjamini–Hochberg adjusted) and
an absolute fold-change ≥ 1. Rows represent miRNAs and columns represent samples and groups.
A box and whisker plot of miRNA Z-scores is shown at the bottom of the heatmap.
To determine the most meaningful miRNAs in terms of predicting disease status and
disease stage, a multinomial elastic-net penalised regression model was constructed using
the 80 differentially expressed miRNAs as predictors and age range groups as outcome.
This resulted in a refined signature of 41 miRNAs with an area under curve (AUC) of
0.803 by receiver operating characteristic (ROC) analysis; see Figure 8. Of these miRNAs,
miR-122-5p, miR-192-5p, miR-206 and miR-34a-5p were shown to increase in expression
across age groups and with higher expression levels in MNGIE, compared to all healthy
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control age range groups. In addition, miR-362-5p revealed a decreased expression with
age in patients with MNGIE, compared to healthy controls.
Figure 8. Refined miRNA signature consisting of 41 miRNAs identified after conducting a multino-
mial elastic-net regression analysis of the 80 differentially expressed miRNAs. These miRNAs were
selected based on their model coefficients not being shrunk to zero after cross-validation of the model
fit.
2.4.4. NormFinder Analysis
One of the objectives of the candidate screening study was to identify candidate
miRNAs that would be suitable to use as normalisers in the downstream qPCR validation
study. The Normfinder algorithm was used to identify suitable reference miRNAs, and
Table 3 shows the top ten miRNAs that were most stably expressed across all samples. On
the basis of those results, miR-30e-5p, miR-425-5p, let-7i-5p and let-7b-5p were selected as
potential normalisers for the qPCR validation phase.
Int. J. Mol. Sci. 2021, 22, 3681 15 of 50
Table 3. The ten most stably expressed miRNAs across all samples analysed by NGS. Stability was
calculated by Normfinder. A low stability value indicates good stability. The tags per million mapped
reads (TPM) is an estimate of the abundance of the miRNA across the MNGIE and healthy control
groups.
Name Stability/Mean TPM Stability Mean TPM
hsa-miR-30e-5p 0.142288503 262.38 1844
hsa-miR-425-5p 0.277956693 706.01 2540
hsa-let-7i-5p 0.296527468 1597.69 5388
hsa-let-7b-5p 0.306335853 11,346.68 37,040
hsa-miR-148a-3p 0.31205228 1122.14 3596
hsa-miR-142-5p 0.334079031 524.17 1569
hsa-miR-21-5p 0.341387813 969.2 2839
hsa-let-7a-5p 0.35729798 8206.42 22,968
hsa-miR-146a-5p 0.361150677 1227.19 3398
hsa-miR-93-5p 0.374529201 942.69 2517
2.5. Validation Phase
The two aims of this study phase were firstly to determine whether the method of
blood sample preparation (serum or plasma) affected the measurement of miRNAs and
secondly to verify the findings of the candidate screening study and finalise a miRNA panel.
The 80 significantly differentially expressed miRNAs; the four contender normalisers that
were identified in the candidate screening study; and a few other differentially expressed
miRNAs of interest were selected for qPCR analysis.
2.5.1. Extraction Efficiency and Sample QC
The efficiency of RNA extraction was monitored by employing a subset of synthetic
miRNAs that simulate high (UniSp2) and medium (UniSp4) expression signals. With the
exception of plasma samples from three patients (PP8, PP11 and PP12) and two healthy
controls (PC5 and PC 13), which showed higher raw quantification cycle (Cq) values,
the steady expression levels of these spike-ins indicate that the extraction efficiency was
similar for the majority of samples (Figure A7). Complementary DNA (cDNA) synthesis
and qPCR efficiency were controlled by the inclusion of spike-ins UniSp6 and UniSp3,
respectively. These miRNA spike-ins were shown to be expressed at a consistent level in
all samples, including the blank assay, thereby indicating that the reverse transcription and
qPCR were successful and none of the samples contained inhibitors (Figure A7).
Sample mRNA signals were examined by the measurement of miR-103, miR-30c, and
miR-23a which are expressed at a consistent level in a majority of sample types. Higher Cq
values were seen in serum samples collected from four healthy controls (SC37, SC38, SC39
and SC41), and three plasma samples (patient: PP1 and PP12; healthy control: PC5) indicating
lower miRNA content in these samples. Interestingly, the four healthy control plasma samples
affected were all collected from individuals who were aged ≤13 (Figure A7). miR-142-3p,
which is highly expressed in platelets, was also measured to assess sample contamination by
this cell type. The results showed a steady level of expression across all samples (Figure A7).
Sample contamination by miRNAs released as a result of sample haemolysis was assessed
from the dCq value of (miR-23a–miR-451a). All samples had a value less than 7, indicating
that the collected samples were not affected by erythrocyte miRNA contamination (Figure A7).
No samples were excluded from the final analysis.
2.5.2. Determination of the Most Stable Reference Genes
Of the 95 miRNAs present on the miRNA PCR panel, 15 assays were detected in all serum
and plasma samples, with an average detection of 64 assays per sample; see Figure A8.
Using NormFinder, the stabilities of the global miRNA profiles detected in all plasma
and serum samples were examined and the top ten most candidate reference miRNAs were
identified. miR-30e-5p and miR-15b-5p provided the lowest stability values of 0.00460 and
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0.00577, respectively, and when combined provided a stability score of 0.00347. Thus, the
average Cq values of these two miRNAs for each sample were employed as the normalisers.
To evaluate the extent to which normalisation reduced data dispersion across each sample,
box and whisker plots were employed; with the exception of one disease sample and
one healthy control sample, these evaluations generally demonstrated a consistent data
distribution; see Figure A9.
2.5.3. Identification of Differentially Expressed miRNA in MNGIE Plasma and Serum
Samples
A comparison between the MNGIE and healthy groups using the students two-
tailed t-test revealed 44 differentially expressed miRNAs in plasma and nine differen-
tially expressed miRNAs in serum. Following adjustment for false discovery rate using a
Benjamini–Hochberg correction at a significance level of p < 0.05 and filtering data with a
Log2 fold change > 1 (upregulated) and < −1 (downregulated), the data sets were reduced
to 33 plasma miRNAs of which 27 were upregulated and 6 downregulated, and three
serum miRNAs were upregulated; see Figure 9 and Table 4. Seventeen of these miRNAs
are common to the refined serum miRNA signature established following the construction
of a multinomial elastic-net penalised regression model of the sequencing data.
Figure 9. Volcano plots of differentially expressed miRNAs in plasma (left panel) and serum (right
panel) showing the relationship between expression fold change and statistical significance. The ver-
tical lines correspond to a 2-fold change in up and down expression, while the horizontal line
represents a p-value of 0.05. The red points represent miRNAs with no statistical significance after
Benjamini–Hochberg correction and a fold change < 2 or > -2, whereas the blue points represent
statistically significant up or downregulated miRNAs.
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Table 4. Differentially expressed miRNAs detected by qPCR in the plasma and sera of patients with MNGIE compared to healthy controls.




hsa-miR-34a-5p * 3.14095 Up 0.000072
hsa-miR-142-3p −2.68394 Down 0.000072
hsa-miR-107 * −1.05870 Down 0.000072
hsa-miR-363-3p * 1.47048 Up 0.000115
hsa-miR-193a-5p * 2.86444 Up 0.000115
hsa-miR-423-5p * 1.48452 Up 0.000209
hsa-miR-660-5p 1.36373 Up 0.000285
hsa-miR-92a-3p 1.07172 Up 0.000285
hsa-miR-378a-3p 1.84138 Up 0.000419
hsa-miR-4732-5p 2.48124 Up 0.000419
hsa-miR-501-3p * 1.80138 Up 0.000449
hsa-miR-486-5p 1.66803 Up 0.000540
hsa-miR-502-3p * 1.28134 Up 0.001049
hsa-miR-215-5p * 1.84928 Up 0.001049
hsa-miR-411-5p * −1.45695 Down 0.001049
hsa-miR-320a * 1.27269 Up 0.001196
hsa-miR-629-5p * 1.46049 Up 0.001413
hsa-miR-193b-3p 3.02042 Up 0.001799
hsa-miR-10b-5p * 1.4974 Up 0.001838
hsa-miR-370-3p −1.70755 Down 0.003432
hsa-miR-885-5p 2.89025 Up 0.004502
hsa-miR-192-5p * 1.60991 Up 0.005376
hsa-miR-183-5p 1.60648 Up 0.005376
hsa-miR-874-3p * 1.15817 Up 0.006205
hsa-miR-122-5p * 2.83981 Up 0.008159
hsa-miR-194-5p 1.67026 Up 0.008929
hsa-miR-340-3p * −1.65444 Down 0.008929
hsa-miR-1180-3p 1.61073 Up 0.010158
hsa-let-7b-3p * 1.04539 Up 0.013040
hsa-miR-483-5p 2.97892 Up 0.014706
hsa-miR-486-3p 1.21158 Up 0.016641
hsa-miR-199a-5p −1.34595 Down 0.022482
hsa-miR-1285-3p 1.54743 Up 0.031837
Serum
hsa-miR-215-5p 1.23468 Up 0.023866
hsa-miR-34a-5p 1.50986 Up 0.025611
hsa-miR-192-5p 1.02344 Up 0.026616
* miRNAs common to the refined miRNA signature established following the construction of a multinomial elastic-net penalised regression model of the sequencing data.
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2.5.4. Meta-Analysis of qPCR and Sequencing Data
In order to corroborate results across the candidate screening and validation phases,
a meta-analysis of the qPCR and NGS data was performed. A meta-analysed combined
p-value was calculated for each miRNA for serum miRNA-seq/plasma qPCR and serum
miRNA-seq/serum qPCR and the p-values ranked; see Table 5. A combined p-value from
the meta-analysis of MNGIE versus control was set at a threshold of < 0.0001, resulting
in a panel of five plasma miRNAs (miR-192-5p, miR-193a-5p, miR-194-5p, miR-215-5p and
miR-34a-5p) and a panel of three serum miRNAs (miR-192-5p, miR-194-5p and miR-34a-5p).
Table 5. Combined p-values and ranking of the top 10 miRNAs after meta-analysis of MNGIE versus
healthy control considering serum miRNA-seq and qPCR (plasma and serum).
Plasma Serum
miR Combinedp-Value Rank miR
Combined
p-Value Rank
hsa-miR-34a-5p 1.38598 × 10−9 1 hsa-miR-34a-5p 3.75631 × 10−7 1
hsa-miR-192-5p 1.68099 × 10−7 2 hsa-miR-192-5p 7.64172 × 10−7 2
hsa-miR-193a-5p 2.07056 × 10−6 3 hsa-miR-194-5p 2.61277 × 10−5 3
hsa-miR-194-5p 5.05358 × 10−6 4 hsa-miR-215-5p 0.000294246 4
hsa-miR-215-5p 1.64213 × 10−5 5 hsa-miR-122-5p 0.00250717 5
hsa-miR-22-3p 0.000128536 6 hsa-miR-193a-5p 0.004645046 6
hsa-miR-10b-5p 0.000169857 7 hsa-miR-193b-3p 0.012087665 7
hsa-miR-363-3p 0.000235272 8 hsa-miR-485-3p 0.019741786 8
hsa-miR-107 0.000294182 9 hsa-miR-885-5p 0.022468769 9
hsa-miR-122-5p 0.000473464 10 hsa-miR-10b-5p 0.035076107 10
2.5.5. Elucidation of MNGIE miRNA Panel
In order to define a final MNGIE disease miRNA panel for the overall study, binary
logistic regression analyses were conducted by regressing each miRNA independently to
the main end-point (disease versus healthy). The results from these analyses demonstrated
that the miRNAs identified from the meta-analyses still retained a high level of statistical
significance (Table A3).
To evaluate whether these five miRNAs could serve as potential biomarkers for
MNGIE disease, ROC curve analyses were performed independently on each of the re-
gression models constructed. ROC analysis demonstrates the trade-off between sensitivity
and specificity and a good biomarker should display both high sensitivity and high speci-
ficity. ROC curves for each miRNA in plasma and serum are shown in Figure 10. The
AUC quantifies the biomarker potential for each candidate miRNA, where the higher the
value, the better the candidate miRNA is in distinguishing MNGIE disease from healthy
controls. Each of the five plasma miRNAs, miR-34a-5p, miR-193a-5p, miR-215-5p, miR-192-
5p and miR-194-5p yielded AUC values of 0.977 (95% confidence interval (CI), 0.938–1,
p= 0.019), 0.941 (95% CI, 0.867–1, p = 0.004), 0.908 (95% CI, 0.813–1, p =0.002), 0.850 (95%
CI, 0.711–0.988, p = 0.005) and 0.804 (95% CI, 0.642–0.966, p = 0.009), respectively (Figure
10). The combined model for the five plasma miRNAs results in a perfect prediction with
an AUC= 1. The three serum miRNAs, miR-34a-5p, miR-192a-5p and miR-194-5p had AUC
values of 0.908, (95% CI, 0.813–1, p = 0.010), 0.824 (95% CI, 0.672–0.975, p = 0.005) and 0.803
(95% CI, 0.642–0.963, p = 0.013), respectively (Figure 10). The combined model for the three
serum miRNAs provides an AUC of 0.851 (CI, 0.703–0.999). These results therefore reveal
the probability of these miRNAs as biomarkers of MNGIE.
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Figure 10. Receiver operating characteristic (ROC) curve analyses to evaluate the diagnostic power of plasma and serum
miRNAs. Plasma miR-34a-5p, miR-193a-5p, miR-215-5p, miR-192-5p and miR-194-5p, healthy controls vs. MNGIE patients
(left panel); and serum miR-34a-5p, miR-192a-5p and miR-194-5p, healthy controls vs. MNGIE patients (right panel). An area
under curve (AUC) of 0.5 is considered significant.
2.6. Performance Phase
The clinical utility of the validated miRNA panel was assessed by examining the
expression fold change of the miRNA panel in the plasma of four patients, A, B, C and D
who received up to 2, 5, 14 and 62 infusions of EE-TP respectively (Figure 11). The largest
responses in terms of a sustained reduced expression, were noted in patient D, who also
showed the greatest clinical and biochemical responses to EE-TP therapy. Clinical responses
included improved MRC sum and sensory sum scores, improved distal sensation and
weight gain. Biochemical improvements included metabolic correction of plasma thymi-
dine and 2′-deoxyuridine concentrations and normalisation of creatine kinase activities
(Table 6). Smaller decreases in the expression of all miRNAs were recorded for patients B
and C at 3 and 4 months of therapy, respectively. Both patients demonstrated reductions in
the plasma metabolites and patient C gained 2.9 kg in weight and reported a reduction in
nausea and vomiting (Table 6). The subsequent increase in the miRNAs in patient C at 11
months of therapy coincided with intestinal bacterial overgrowth and the commencement
of totalparenteral nutrition (TPN) for weight loss. Patient A demonstrated a decrease in the
expression of miR-34a-5p only. Clinical improvements in this patient included a greater ap-
petite, tingling sensations in the feet compared to no sensation pre-therapy and improved
swallowing and dysgeusia. Biochemically, there were reductions in both thymidine and
2′-deoxyuridine.
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Figure 11. miRNA panel expression fold-changes during treatment with erythrocyte encapsulated thymidine phosphorylase
(EE-TP) compared to baseline expression levels for patients A, B and C (left panel) and patient D (right panel).
Clinical observations and plasma metabolite concentrations during EE-TP therapy
and at the time of miRNA assessment are reported in Table 6.
2.7. Target Gene Prediction and Enrichment Analysis
To annotate and speculate on the role of the five differentially expressed miRNAs,
target genes of each individual miRNA were predicted using four databases. To be in-
cluded in further enrichment analyses a gene target was required to be predicted in 2 of
the 4 databases. A total of 536 downregulated genes were identified which were then
subjected to Gene Ontology (GO) function analysis. Applying a threshold p-value <
0.05 revealed the enriched GO terms shown in Figure 12. In the molecular function asso-
ciated category, the differentially expressed miRNAs were significantly associated with
the following three terms: cytoskeletal protein binding (GO:0008092), calcium ion binding
(GO:0005509) and molecular function regulator (GO:0098772). GO analysis of the biological
processes-associated category showed that differentially expressed miRNAs were most
significantly associated with the following terms: cell adhesion (GO:0007155), biological
adhesion (GO:0022610), cell-cell adhesion (GO:0098609), cell–cell via plasma-membrane
adhesion molecules (GO:0098742) and homophilic cell adhesion via plasma membrane
adhesion molecules (GO:0007156). The most significant GO cell component associated
terms of differentially expressed miRNAs included the following: plasma membrane
part (GO:0044459), integral component of membrane (GO:0016021), intrinsic component
of membrane (GO:0031224), integral component of plasma membrane (GO:0005887), in-
trinsic component of plasma membrane (GO:0031226), plasma membrane, (GO:0005886)
membrane part (GO:0044425), cell periphery (GO:0071944) and neuron projection termi-
nus GO:0044306).
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Table 6. Clinical observations and plasma metabolite concentrations at baseline and during treatment with EE-TP and at the time of miRNA assessment.
Patient







A Pre-therapy(37 years) - 10.5 18.8
Sensorimotor polyneuropathy, external ophthalmoplegia,
leukoencephalopathy, intestinal dysmotility with cachexia.
Weight:40.6 kg
1 129 0.5 0.3 No changes observed
2 129 1.1 4.1
Greater appetite, experienced tingling sensations in feet
compared to no sensation pre-therapy, improved
swallowing and dysgeusia, tongue less glossitic.
Weight: 40.6 kg
B Pre-therapy(26 years) - 12 19
Sensorimotor polyneuropathy, external ophthalmoplegia,
intestinal dysmotility, anorexia and cachexia. Weight: 31.7
kg
3 108 2.1 3.9 No changes observed
C Pre-therapy(25 years) - 9.0 19.0
Sensorimotor polyneuropathy, external ophthalmoplegia,
intestinal dysmotility, anorexia and cachexia.
Weight:32 kg
4 9 5.09 16.0 Reduction in nausea and vomitingWeight: 34.9 kg
11 29 4.6 10.8
Intestinal bacterial overgrowth, commencement of TPN
for weight loss between months 7 and 10.
Weight: 35 kg
D Pre-therapy(28 years) - 21.0 31.0
Sensorimotor polyneuropathy, external ophthalmoplegia,
minimal intestinal dysmotility. MRC sum score: 56,
sensory sum score: 21. Creatine kinase:1200 U/L. Weight
57.4 kg
4 29 0.0 0.0 Improved distal sensation. Creatine kinase: 448 U/L.Weight: 59 kg
18 47 0.0 0.0 MRC sum score: 74, sensory sum score: 19.Creatine kinase:406 U/L. Weight 63.2 kg
58 47 0.0 0.2 MRC sum score: 74, sensory sum score: 19. Creatinekinase: 272 U/L. Weight 59 kg
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Figure 12. Gene Ontology (GO) analysis of the target genes for the five differentially expressed
miRNAs. Top panel: significantly associated terms for molecular functions; middle panel: top
20 significantly associated terms for biological processes; and bottom panel: significantly associated
terms for cell components. The terms are ordered by Kologorov–Smirnov p-value (−log) with the
x-axis showing the –log10 p value for each GO term. Vertical lines from left to right show equivalents
of p = 0.05, p = 0.01 and p = 0.0001.
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis
showed that differentially expressed genes in the miRNA-mRNA regulatory network
were enriched in six pathways: the notch signalling pathway (KEGG:04330), adherens
junction (KEGG:04520), p53 signalling pathway (KEG: 04115), pancreatic cancer (KEG:
05212), glycosaminoglycan biosynthesis—heparan sulphate/heparin (KEGG: 00534) and
N-glycan biosynthesis (KEGG: 00510); see Table 7.
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Table 7. KEGG pathway analysis of miRNA target genes.
Pathway Target Genes p-Value FDR p-Value
Notch signaling pathway APH1A, DLL1, JAG1,NOTCH1, NOTCH2, NUMBL 1.1 × 10
−5 0.0024
Adherens junction LEF1, MET, NECTIN1,PTPRM, SMAD4, WASF1 0.0002 0.0143
p53 signalling pathway CCNE2, CDK6, EI24, IGFBP3,MDM4, SERPINE1 0.0001 0.0143




GLCE, NDST1, XYLT1 0.0008 0.0460
N-Glycan biosynthesis B4GALT2, FUT8, MGAT4A,MGAT5B 0.0012 0.0473
A network of the five differentially expressed miRNAs and predicted genes targeted
by more than two of the miRNAs was constructed (Figure 13). The results show that no
gene was targeted by than more than three miRNAs; two genes (CLIP3 and GPR22) were
the target of three of the differentially expressed miRNAs and 52 genes were targeted by
two of the miRNAs.
Figure 13. MicroRNA-target gene network for the upregulated miRNA panel in MNGIE. The network
shows the relations of the five upregulated miRNAs and their potential target genes. The outer ring
represents genes that are targeted by 2 miRNAs. The inner ring containing genes that are targeted by
3 of the miRNAs.
3. Discussion
Clinical outcome measures are employed as a means to accurately assess the efficacy
of a treatment in terms of benefit (improved health) or risk (e.g., adverse reactions, hos-
pitalisations, and death) and therefore selecting the most meaningful measure is crucial
for the design of a valid clinical trial. Indisputably, many potentially effective drugs have
failed to demonstrate efficacy due to the selection of inappropriate outcome measures.
The development of outcome measures for rare diseases is however, particularly challeng-
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ing given disease phenotypic heterogeneity, variable time frames for disease progression
and incomplete knowledge of the disease pathophysiology. Regulators acknowledge the
need for accelerating the rare disease drug development pathway and may approve a
biomarker endpoint measure in the absence of validated endpoint measures for the in-
tended patient population. Examples of rare disease drugs that have received approval
based on biomarker primary endpoints include tiopronin for cystinuria (biomarker: re-
duction in urinary excretion of cystine) sapropterin dihydrochloride for phenylketonuria
(reduction in plasma phenylalanine), agalsidase beta for Fabry disease (reduction of globo-
triaosylceramide storage granules in biopsied kidney interstitial capillaries), imiglucerase
for Gaucher disease type I (composite of biomarker endpoints, including haemoglobin and
platelet count) and sebelipase alfa for lysosomal acid lipase deficiency (normalisation of
serum alanine aminotransferase levels) [28–32].
MNGIE is a complex multisystem disorder where patients present with a combination
of cachexia, gastrointestinal dysfunction, and neuromuscular dysfunction; currently there
are no validated clinical outcome measures which provide objective assessments of the
clinical status of the patient. The identification of a biomarker for MNGIE would very likely
lead to improved patient outcomes through accelerating patient access to new therapies,
enabling early intervention and assessment of treatment efficacy. One of the recommenda-
tions of the recently published output from International Consensus Conference on MNGIE
was the application of multi-omics analyses for the purpose of identifying biomarkers that
fingerprint the main clinical features of the disease [33].
The discovery that miRNAs are detectable in extracellular biofluids has raised much
interest in their potential as early non-invasive biomarkers for diseases. Studies reporting
alterations in miRNA expression profiles in patients with muscular and neurological
disorders led us to conduct a feasibility study in patients with MNGIE [27,34,35]. In this
study we reported a significant dysregulation of 82 miRNAs in the serum of patients
compared to age and sex matched healthy controls, however, a critical limitation of this
study was the small number of patients recruited (n =5). Previous to this feasibility study,
Yong et al. reported a miRNA profiling study in a single patient with MNGIE and a cohort
of heterozygous family members, using a microarray-based screening [36].
To investigate the clinical applicability of circulating miRNAs as biomarkers of MNGIE
with improved experimental rigour, we conducted an expanded expression miRNA pro-
filing study whereby we recruited three further patient cohorts through an international
collaborative effort. The workflow employed a rigorous four-phase methodological study
design, incorporating a power analysis, sample and data quality control steps, spike-in
controls, normalisers and candidate validation using RT-qPCR. For the candidate screening
phase, NGS was employed for miRNA expression analysis, a state-of-the art technology
which is suited for unbiased genome-wide miRNA expression profiling. For the discov-
ery, candidate validation and performance phases, RT-qPCR was used, the gold standard
method for expression profiling, having a high specificity and linear dynamic range of
quantification. Since there are no standard reference or housekeeping miRNAs, potential
normalisers were identified in the candidate screening stage. These were included in the
custom miRNA qPCR panel employed in the validation phase where the stabilities of the
global miRNA profiles detected in all samples were examined using NormFinder.
From the discovery phase it was noted that 10 of the 14 upregulated miRNAs and
7 of the downregulated miRNAs were previously identified in our published feasibility
study [27]. Although unsupervised clustering analysis of the discovery data revealed a
natural separation between healthy control and patient serum samples, and showed that
the miRNA profile within the healthy control group was similar, it exhibited a greater
variability in MNGIE samples, based on pairwise Euclidean distances. MNGIE is a pro-
gressive disorder, with an average diagnosis age of 18 years and a mean death age of
37.6 years, and thus we hypothesised that the variability noted in the MNGIE samples
could be attributed to the stage of the disease affecting the miRNA expression profile.
Thus, for the candidate screening phase we included an expression analysis of three patient
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sub-groups: ≤19, 20–29 and ≥30 years of age, these broadly representing early, middle and
late disease stages. As a whole, the genome-wide miRNA expression profiling study of the
candidate screening phase, revealed 80 candidate miRNAs with discriminative potential
between patients with MNGIE and healthy controls; 55 of these were upregulated and
25 were downregulated in MNGIE. Through the construction of a multinomial elastic-net
penalised regression model whereby the 80 differentially expressed miRNAs were pre-
dictors and age range groups were outcomes, the signature was refined to 41 miRNAs.
Of these, miR-122-5p, miR-192-5p, and miR-34a-5p were shown to increase in expression
across age groups and with higher expression levels in patients aged ≤ 19, compared to
all healthy control age range groups. One of the typical features of full-blown MNGIE
is the hepatic steatosis and cirrhosis, either disease related or induced by the long-term
use of TPN. Interestingly, all three miRNAs have previously been shown in a number of
studies to be associated with liver pathology, and consequently have been proposed as
useful diagnostic biomarkers of liver injury [37–40]. The overexpression pattern of these
miRNAs across the three disease age groups may therefore be explained by progressing
liver pathology. The prognostic value of these miRNAs in predicting disease severity will
require longitudinal validation using a uniform methodical study design; a limitation of
this study is that the extent of disease progression was not scored in the patients recruited.
Of note, the 20–29 age group patient group demonstrated overexpression of the haemolysis-
related miRNAs (miR-451a, miR-16-5p, miR-486-5p, miR-15a-5p and miR-15b-5p) compared
to healthy controls [41]. Although results from the quality control analysis demonstrated
the dCp(miR23a-miR451a) levels were higher in the patient samples (range 0.2-2.5, samples
SP 3, 4, 11, 14, 24, 25 and 26) compared to healthy control samples (range 0.9 to 1.1, samples
SC 3, 4, 11, 14, 24, 25 and 26), these were well below the value that would normally indicate
haemolysis. A more comprehensive understanding of the natural history study of MNGIE
is also urgently required to enable disease progression quantification, identify outcome
measures and assess the efficacy of investigational therapies; exploratory novel biomarkers
such as miRNAs should be included in such studies.
As part of the validation phase, we aimed to determine whether the choice of blood
biofluid had an effect on the miRNA profile. Numerous studies report the use of both blood
fractions for identifying miRNA biomarkers in different pathological conditions. However,
serum and plasma are often treated as similar or equivalent matrices and publications
often fail to report the justification for their selection. Whereas plasma is the fluid that
remains when blood coagulation is prevented through the addition of an anticoagulants,
serum is the fluid that remains after allowing the blood to coagulate and doesn’t contain
fibrinogens. The different preparation procedures have the potential to impact on miRNA
recovery, making it difficult to compare data between studies using different matrices.
In the current study, plasma and sera were collected from the same patients and healthy
controls and processed downstream using identical procedures to determine whether there
were any substantial differences in miRNA expression profiles between the two biofluids.
A comparison between MNGIE and healthy control groups revealed 33 plasma miRNAs
of which 27 were upregulated and 6 downregulated, and 3 upregulated serum miRNAs.
Thus, this investigation confirms that the type of biofluid is a biological variable that has
a large impact on the miRNA profile; compared to serum, plasma demonstrated a better
detection of miRNAs when using qPCR, and the use of this biofluid in future studies is
highly recommended. Potentially critical variables that contribute to these differences
are the extent to which samples are subjected to haemolysis or platelet activation during
processing, which could lead to the release of miRNAs and ribonucleases. Samples in
this study were assessed for miRNAs which are released during these processes and were
shown not to be over-expressed. The reason for the differences in miRNA expression
between the two biofluids in this study is not known, but other considerations are the
adsorption of miRNAs within the blood clot or the separator gel, leading to an artefactual
depletion of miRNAs in serum. This investigation emphasises the importance of ascertain-
ing the optimal biofluid fraction to employ and is an essential determinant if comparisons
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are to be made between different studies and thus ultimately advance miRNA biomarker
discovery. Of note, 17 of the miRNAs detected by qPCR were common to the refined
serum miRNA signature obtained following the construction of a multinomial elastic-net
penalised regression model of the sequencing data.
To comprehensively assess the accuracy of circulating miRNAs biomarkers of MNGIE
we performed a meta-analysis of the qPCR and sequencing data; this resulted in a panel of
five significantly upregulated plasma miRNAs (miR-192-5p, miR-193a-5p, miR-194-5p, miR-
215-5p and miR-34a-5p) and a panel of three significantly upregulated serum miRNAs (miR-
192-5p, miR-194-5p, and miR-34a-5p) which were common to the plasma panel. Each miRNA
retained a high level of statistical significance following binary regression analyses and
showed considerable diagnostic power from the AUC values of ROC analysis. Furthermore,
the recombination of the plasma miRNA panel exhibited a perfect prediction of AUC=1.
The single best predictor of MNGIE is miR-34a-5p, having an AUC of 0.977 and was shown
to be elevated across each age sub-group of disease, when compared to any healthy group.
A decrease in expression of miR-34a-5p was noted during treatment with EE-TP in all four
patients. Clinical responses recorded at the same time as sampling for miRNA analysis
were generally associated with gastrointestinal features, including weight gain, improved
appetite, swallowing and dysgeusia. An increase in expression of the miRNA panel was
noted in patient C at 11 months and this coincided with intestinal bacterial overgrowth and
commencement of TPN for weight loss in the preceding 4 months. Although deceases in
plasma thymidine and 2′-deoxyuridine were observed in all four patients, only patient D
was able to attain (and sustain) total metabolic correction, and intriguingly also sustained a
decreased miRNA expression profile and an improvement in the peripheral neuropathy.
The performance phase of this study was obviously limited by the number of patients
recruited and absence of longitudinal sampling in two of the patients. To robustly test
the performance of this miRNA panel and correlate miRNA expression profiles with
clinical outcome data, future investigations would benefit from operating in tandem with a
clinical trial of a therapeutic intervention, thereby exploiting the methodological rigor of a
regulatory approved study design.
Theoretical insight into the underlying pathomolecular mechanisms of MNGIE was
accomplished by conducting gene target prediction and enrichment and pathway analyses.
The five upregulated plasma miRNAs, miR-192-5p, miR-193a-5p, miR-194-5p, miR-215-5p
and miR-34a-5p, were selected and their putative gene targets and pathways in which the
putative genes are involved were identified. KEGG pathway analysis (Table 7) revealed that
the most significant pathways were all targets of miR-34a-5p and included Notch signalling,
adherens junction and p53 signalling pathway. Notch signalling is a highly evolutionarily
conserved pathway that regulates the balance between cell proliferation, differentiation
and apoptosis. Relevant previous studies associating miR-34a with the Notch signalling
pathway include that of Wang et al. who observed high expression levels of miR-34a,
a low level of Notch signalling and neuronal apoptosis in the hippocampal neuronal
spontaneous recurrent epileptiform discharges model [42]. In another study, Fan and
co-workers studying age related apoptosis in the human lens epithelial cell, demonstrated
that an overexpression of miR-34a and the subsequent inhibition of its target, Notch 2,
induced mitochondria-mediated apoptosis through permeabilization of the mitochondrial
outer membrane, cytochrome c release and activation of caspase-9 [43]. Thus, it could
be speculated that the pro-apoptotic activity of miR-34a contributes to the degenerative
pathology of MNGIE via mitochondria-mediated apoptosis.
Adherens junctions are plasma-membrane structures that mediate cell–cell adhesion
by linking the plasma membrane to the actin cytoskeleton and are critical for the coordi-
nation of cell polarity, differentiation and signalling. The core molecular components of
the junctions are the nectin–afadin and cadherin–catenin (E-cadherin, β-catenin, α-catenin,
p120-catenin) complexes. A majority of evidence supporting the involvement of miR-34a in
adherens junction signalling appears to have very little relevance to the MNGIE pheno-
type, reporting an inhibitory effect of miR-34a on epithelial-mesenchymal transition and
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cancer progression [44–47]. However, one study that has some commonality with MNGIE
is that of Bukeirat et al. who demonstrated an overexpression of miR-34a leading to an
increased blood brain barrier permeability and the disruption of the tight junction proteins,
Zonula occludens, in cerebrovascular endothelial cells [48]. One of the clinical hallmark
features of MNGIE is the leukoencephalopathy, a result of blood-brain barrier dysfunction
leading to vasogenic oedema [49]. Although the bioinformatics analysis indicated that
tight junction related genes were not targets of miR-34a, it is now recognised that adherens
junctions and tight junctions are physically linked by the zonula occludens proteins, and
thus this raises the possibly that disruption of the Zonula occludens was mediated via the
inhibitory effects of miR-34a on adherens junction genes [50].
The p53 signalling pathway plays a salient role in co-ordinating the cellular response
to different types of intrinsic and extrinsic stress signals, such as DNA damage, oncogene
activation and hypoxia. In response to a stress signal, the nuclear transcription factor p53 is
activated leading to the transcriptional regulation of the appropriate target genes to induce
cell cycle arrest and/or apoptosis. A number of studies have confirmed that miRNAs play
pivotal roles in the p53 pathway; whereas miRNAs have been reported to regulate the
activity and function of p53 through direct repression of p53 or its regulators, p53 has also
been shown to induce the transcription expression of a number of miRNAs, to promote the
p53 response [51]. miR-192, miR-194 and miR-215, three of the upregulated miRNAs identi-
fied in our study, have been reported to target MDM2 and directly repress the expression
of MDM2, a key regulator of p53, and thereby activate p53 [51–53]. In addition, miR-34a
which was also found to be dysregulated in our study, has been reported to regulate p53
function through targeting a number of p53 negative regulators, including MDM4 and
SIRT1 [52–54]. Other confirmed targets of miR-34a include Bcl-2, E2F3, CDK4/6, and c-Myc,
thereby identifying miR-34a as a promoter of cell cycle arrest and apoptosis [55–58]. Inter-
estingly, miR-192, miR-194, miR-215 and miR-34a are also transcriptionally regulated by
p53, therefore creating positive feedback loops with p53. Recent studies suggest that p53
may have a role in mtDNA homeostasis through its ability to translate to the mitochondrial
matrix and interact with mtDNA polymerase γ in response to mtDNA damage induced
by exogenous and endogenous insults [59]. In their study Achanta et al. demonstrated
that an overexpression of p53 had a negative effect on the normal mitochondrial home-
ostasis, leading to a decrease in mtDNA abundance [60]. mtDNA depletion is one of
the characteristic molecular findings in MNGIE, and it is therefore tempting to speculate
that a miRNA-induced overexpression of p53 may contribute to the process of mtDNA
loss. Experimental investigation is required to substantiate the relevance of the miRNA-
p53 network in MNGIE and specifically, determine whether such interaction represents a
homeostatic mechanism through the elimination of cells with dysfunctional mitochondria,
or conversely, contributes to the disease pathology by amplifying cell damage.
One intriguing report that may be of relevance to the gastrointestinal pathology
of MNGIE is the p53-induced expression of miR-34 leading to the repression of c-kit
expression in colorectal cancer cells via a conserved seed-matching sequence in the c-Kit
3′-UTR [61]. It is established that c-Kit is expressed in the interstitial cells of Cajal, the
pacemaker cells located in the smooth muscle layers of the gastrointestinal tract, and which
respond to enteric motor neurotransmitters [62]. The corresponding ligand of c-Kit is stem
cell factor (SCF), which is synthesised by the smooth muscle cells of the gastrointestinal
tract. The SCF/c-Kit signalling pathway is essential for normal development, maturation,
and survival of interstitial cells of Cajal, and is required for maintaining their phenotype and
functional networks. The inhibition of and loss-of-function mutations in c-Kit has shown to
be associated with the trans-differentiation of interstitial cells of Cajal to a smooth muscle-
like phenotype and gastrointestinal dysmotility disorders [63–65]. MNGIE is commonly
associated with chronic intestinal pseudo-obstruction leading to severe gut motility failure.
Examination of the small intestine neuromuscular pathology in patients with MNGIE has
shown an absence of c-Kit-positive interstitial cells of Cajal around the myenteric plexus,
intermuscular septa and within muscular plexus, which may be associated with cell death
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or trans-differentiation into a smooth muscle phenotype [66,67]. The plausible contribution
of miR-34a to the pathomolecular mechanisms that underly the gastrointestinal aspects of
MNGIE deserves further investigation.
Due to base-pair complementarity, a single miRNA is able bind to and regulate many
mRNAs, and one mRNA can be regulated by multiple miRNAs. To visualise the miRNA-
target interactions we constructed a network of our validated miRNAs and their predicted
genes targeted by more than two of the miRNAs. Two candidate genes, CLIP3 and GPR22
were the target of three of the differentially expressed miRNAs (miR-215, miR-34a and
miR-192) and 52 candidate genes were targeted by two of the five miRNAs. CLIP3 encodes
for cap-gly domain-containing linker protein 3 (CLIP3) and is associated with the plasma
membrane and trans-Golgi membrane [68]. Studies in the rat have shown that CLIP3
is highly expressed in neurones and glial cells and is associated with myelination and
nerve tissue regeneration after peripheral nerve injury [69,70]. Accordingly, CLIP3 may
have a role in neuronal homeostasis, possibly through the maintenance of polarised pro-
tein/membrane intracellular trafficking and cytoskeleton remodelling. GPR22 encodes for
the orphan G-protein-coupled receptor, GPR22, and has been reported to be expressed in
many regions of the brain [71]. No ligand has been identified for GPR22 and its biological
function remains poorly understood. It is not clear how or if these genes have any involve-
ment in the pathology of MNGIE, however, both appear to be expressed in tissue systems
that are affected by the disease and thus warrant further investigation.
4. Materials and Methods
4.1. Study Design and Subjects
The study was conducted according to the study design depicted in Figure 1. A total
of 65 patients with MNGIE and 65 age and sex matched healthy controls were recruited
into this study and were assigned to the four study phases: discovery phase, 10 patients
and 10 healthy controls; candidate screening phase, 20 patients and 20 healthy controls;
validation phase, 35 patients and 35 healthy controls; performance phase, 4 patients who
were included in the validation study but subsequently received treatment with EE-TP.
Different participants were recruited into the discovery, candidate and validation phases.
The inclusion criteria for patient eligibility were a definitive diagnosis of MNGIE due to
thymidine phosphorylase deficiency based upon DNA sequencing, and/or < 10% of normal
thymidine phosphorylase activity in the buffy coat; and biochemical criteria. Exclusion
criteria for both patients and healthy controls included participation in a controlled trial of
an investigational medicinal product, receipt of blood transfusions within the past 4 months
and a current or past history of hepatitis B, hepatitis C or human immunodeficiency virus
infection. Due to the rarity of MNGIE, patient recruitment was performed at a number
of international centres. The study was conducted according to the guidelines of the
Declaration of Helsinki, and approved by the NHS Research Ethics Committee (London—
Surrey Borders, reference 18/LO/2173). Written informed consent was obtained from all
participants.
4.2. Blood Collection
Twenty mL of venous blood were collected from each participant into one serum (SST)
and/or one K2EDTA-treated BD Vacutainer tubes (Beckman Dickinson, Berkshire, UK) using
a standard phlebotomy protocol. For patients treated with EE-TP, blood was collected prior
the administration the treatment cycles listed in Table 6 so as to concur with the clinical
observations recorded. Blood collected into serum tubes were left at room temperature for 30
min to permit coagulation, whereas blood collected into anticoagulant was mixed by gently
inverting the tubes 10 times and then processed immediately. Both tubes were centrifuged at
1500× g for 10 min at 4 ◦C. Following centrifugation, the serum and plasma supernatants
were aspirated using RNase-free pipette tips and apportioned into RNase-free cryotubes as
0.5 mL aliquots and then stored at −80 ◦C until required for miRNA extraction. Samples
were visually inspected for pink colouration and those which indicated haemolysis were
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excluded from the study. miRNA profiling for the different study phases using qPCR or
NGS was then conducted according to the workflow as presented in Figure 14 and described
in detail below.
Figure 14. Schematic diagram of miRNA profiling workflow for the different study phases using
NGS and qPCR.
4.3. miRNA RT-qPCR
miRNA profiling using RT-qPCR was performed in serum and plasma samples col-
lected for the discovery, validation and performance study phases (Figure 14).
4.3.1. RNA Isolation and Sample Quality Control
Prior to profiling using miRNA qPCR panels, samples were first subjected to a number
of quality control checks to ensure the absence of unwanted bias arising from pre-analytical
or analytical variables, and to establish that the quality of the RNA input was sufficiently
high for effective amplification.
Serum and plasma samples were thawed on ice and then centrifuged at 3000× g for
5 min in a 4 ◦C microcentrifuge to remove cryoprecipitates. Two hundred microlitres of
each plasma or serum sample were transferred to a new tube, to which 60 µL of lysis
solution BF containing 1 µg carrier-RNA/60µL lysis solution BF and 1 µL RNA spike-in
template (UniSp2 and UniSp4 which detect differences in RNA extraction efficiency) were
added. After mixing for 1 min and incubation at room temperature for 7 min, 20 µL
protein precipitation solution BF was added, and the mixture was vortexed and incubated
at room temperature for 1 min. Following centrifugation at 11,000× g for 3 min, total
RNA was extracted from the supernatants using the miRCURY RNA isolation Kit for
Biofluids. The purified RNA was eluted into 50 µL nuclease-free water and stored at
−80 ◦C until analysis.
First-strand cDNA was synthesised from each RNA sample using the miRCURY
LNA RT kit (Qiagen, Hilden, Germany) and tested for the expression of the endogenous
miRNAs, miR-103, miR-23a, miR-30c, miR-451 and miR-142-3p which are typically expressed
in biofluids. The expression of the three-synthetic spike-ins was also examined (UniSp2,
UniSp4 and UniSp6). Briefly the RNAs were tailed with a poly(A) sequence at their 3′end
and then reverse transcribed into cDNA using a universal poly(T) primer with a 3′end
degenerate anchor and a 5′end universal tag; one reaction contained 4 µL of template RNA
(5 ng/µL), 4 µL of 5× SYBR Green Reaction Buffer, 2 µL of 10 × RT enzyme, 1 µL RNA
spike in (UniSp6 which evaluates the efficiency of the cDNA synthesis reaction for signs
of inhibition) and 9 µL nuclease-free water. To detect RNA contamination in the reverse
transcription reaction (RT), negative controls excluding template were included in the
RT step. RT reactions were incubated in a thermocycler for 60 min at 42 ◦C and then 5
min at 95 ◦C to inactivate the reaction. Immediately after incubation, cDNA was diluted
50x by the addition of nuclease-free water. Quantitative PCR (qPCR) was performed in
Int. J. Mol. Sci. 2021, 22, 3681 30 of 50
a total volume of 10µL according to the miRCURY LNA miRNA PCR protocol. Briefly
one reaction contained 5 µL 2x SYBR Green Master Mix, 1 µL forward and reverse PCR
primer mix, 3 µL of diluted cDNA template and 1 µL nuclease-free water. Amplification
was performed in a LightCyler 480 Real-Time PCR system (Roche, Basel, Switzerland) in
384 well plates at 95 ◦C for 2 min, 45 cycles of 95 ◦C for 10 s and 56 ◦C for 60 s, and this
was followed by melting curve analysis at 60–95 ◦C.
The expression levels of the endogenous miRNAs and spike-ins were examined; any
sample outliers would be excluded from any further analysis. Sample haemolysis was
assessed from the differential of endogenous miR-23a-3p and miR-451, where miR-451 is
normally expressed within erythrocytes and miR-23a is stably expressed in plasma and
serum and is not affected by haemolysis. A delta Cq (miR23a-miR451) value greater than 7 is
an indicator haemolysis, and affected samples were removed from downstream analysis.
Signals from the no template negative control were assessed and only miRNAs that elicited
signals at least five Cq-values lower than the negative control were included in the panel
profiling described below. For negative control assays that did not yield any signal, the
upper limit of detection was set to Cq = 37.
4.3.2. miRNA Profiling Using RT-qPCR Panels
Samples that passed the quality control checks above were profiled using miRNA
qPCR panels as follows. RNA was reverse transcribed in 20 µL reactions using the miR-
CURY LNA RT Kit (Qiagen, Hilden, Germany) as described above. cDNA was diluted
50 x and assayed in 10 µL PCR reactions according to the protocol for miRCURY LNA
miRNA PCR. For the discovery phase, each miRNA was assayed once by qPCR on the
miRNA Ready-to-Use PCR, Human panel I+II using miRCURY LNA SYBR Green master
mix (752 assays). For the validation and confirmatory phases, each miRNA was assayed
once by qPCR on the custom designed panel using miRCURY LNA SYBR Green master
mix (95 assays, see Table A4). Negative controls excluding template (no template control)
from the reverse transcription reaction were performed and profiled as the samples. Am-
plification was performed in 384 well plates using the cycling conditions described above.
Melting curve analyses were performed at the end of the PCR cycles.
4.3.3. qPCR Data Collection and Quality Control
Data were analysed following the guidelines for Minimum Information for Publication
of Quantitative Real-Time PCR Experiments (MIQE) [72]. Amplification curves for each
target miRNA were analysed using the Roche LightCyler software to obtain a Cq value,
calculated using the method of the second derivative. To determine the specificity of
the PCR products, a melting curve was generated and analysed for each assay using
the LightCyler software. The appearance of a single peak with the expected melting
temperature was an indication that a single specific product was amplified during the
qPCR process; any reactions that gave rise to multiple melting curve peaks or single
peaks with a melting temperature that was inconsistent with the assay specifications were
removed from the data set. The amplification efficiency was calculated using algorithms
similar to the Lin Reg software. Only assays with 5Cq less than the negative control were
included in the analysis. For assays that did not yield any signal over the negative control,
the upper limit of detection was set to Cq = 37.
4.3.4. Normalisation
Raw Cq data that passed the above quality control criteria were then subjected to
normalisation to control for differences in the amount of RNA added to each reaction.
For the discovery phase, normalisation was performed by first identifying which miRNAs
were detected in all samples, and then taking the average of the identified miRNA Cq values
for each sample. For this study phase this included 137 miRNA assays, as the stability
of the average of these was higher than any single miRNA in the data set as measured
by the Normfinder software [73]. For the validation and confirmatory phases, a custom
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normalisation was applied, based on candidates identified in the miRNA sequencing study
(candidate screening phase) by determining the most stable endogenously expressed genes
for optimal normalisation. Exponentially transformed Cq values (2−Cq) were imported
into the NormFinder software and the stability value of each reference gene was computed,
with genes of the lowest stability values indicating a higher consistency of miRNAs across
different samples and groups. The average stability values of gene combinations were
investigated to assess if the average of these could improve stability with respect to the use
of a single gene. The combination of miR-30e-5p and miR-15b-5p were found to provide
the lowest stability value and therefore the average Cq values of these miRNAs for each
sample was employed as the normaliser. The following formula was used to calculate the
normalised Cq values for each miRNA:
Normalised Cq = average sample Cq (of miRNAs detected in all assays)—assay Cq
(specific miRNA in assay). Thus, a higher value would indicate a greater abundance of a
specific miRNA in a particular sample.
4.3.5. Differential Gene Expression Analysis
Expression differences (∆∆Cq) were calculated between the ∆Cq values of the patient
and control samples (∆Cq patient-∆Cqcontrol). The fold change was calculated as 2-
∆∆Cq, whereby values >1 were considered as upregulation and those values <1 were
considered as downregulation. Significant miRNAs between the control and patient group
were calculated using the two-tailed Student’s t test, with p-values then adjusted for false
discovery rate (FDR) via the Benjamini–Hochberg method. Statistical significance was then
gauged by any variable that passed the adjusted p-value ≤ 0.05.
4.4. miRNA NGS Analysis
miRNA sequencing analysis was performed on serum samples collected for the
candidate screening phase, according to the workflow presented in Figure 14.
4.4.1. RNA Isolation and Quality Control
Prior to library preparation, samples were first subjected to quality control steps using
qPCR to check for sample haemolysis, cDNA synthesis inhibition, RNA isolation efficiency
and to confirm that sample miRNA expression levels were within the expected range.
Plasma samples were thawed on ice, centrifuged at 3000× g for 5 min at 4 ◦C and then
processed for RNA isolation using the miRNeasy Serum/Plasma Kit (Qiagen, Hilden, Ger-
many). Briefly, 1 mL QIAzol Lysis Reagent and 200 µL of plasma sample were mixed and
incubated at room temperature for 5 min before adding 3.5 µL miRNeasy Serum/Plasma
spike-in control containing UniSp 100 and UniSp 101 for the assessment of RNA isola-
tion efficiency, and UniSP132, UniSP133, UniSP135, UniSP137, UniSP138, UniSP140 and
UniSP142 for assessing the reproducibility and linearity of the NGS reads downstream.
Two hundred µL of chloroform were added to each lysate and the tubes thoroughly mixed
by vortexing for 15 s, followed by incubation at room temperature for 3 min and then
centrifugation at 12,000× g at 4 ◦C for 15 min. The upper phase containing the RNA was
transferred to a new collection tube to which 1.5 volumes of 100% ethanol were added and
the sample mixed thoroughly by pipetting. RNA was purified from 700 µL of each sample
using RNeasy MinElute spin column and eluted into a final volume of 12 µL nuclease-free
water.
First-strand (cDNA) was synthesised from each RNA sample using the miRCURY
LNA RT kit (Qiagen, Hilden, Germany) and tested for the expression of miR-103, miR-23a,
miR-30c, miR-451, miR-142-3p and the three-synthetic spike-ins (UniSp 100, UniSp 101 and
UniSp 6) as described above, but using half the volumes of the reaction components. qPCR
was performed in a total volume of 100 µL using 50 µL 2x miRCURY SYBR Green Master
Mix, 1 µL of undiluted cDNA template and 49 µL RNase-free water. Amplification was
performed in 384 well plates using the cycling conditions as described above.
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4.4.2. Library Preparation
The library was prepared using the QIAseq miRNA Library Kit (Qiagen, Hilden,
Germany), where 5 µL of total RNA obtained using the miRNeasy Serum/Plasma Kit
were converted to miRNA NGS libraries. Briefly, a pre-adenylated DNA adapter was
ligated to the 3′ ends of miRNAs, followed by ligation of an RNA adapter to the 5′ end.
A reverse-transcription primer containing an integrated UMI was used to convert the total
3′/5′ ligated miRNAs into cDNA. Following cDNA purification using magnetic beads, the
library was amplified with indexing forward primers and a universal reverse primer using
22 cycles of PCR and then cleaned-up using magnetic beads.
4.4.3. Library Quality Control
Pre-sequencing library quality control and concentrations were performed by analysing
1 µL of the miRNA sequencing library on an Bioanalyzer 2100 (Agilent, California, USA)
using a using a high sensitivity DNA chip. The concentration of the library was then
determined in 2 µL using a Qubit Fluorimeter (Thermo Fisher Scientific, Massachusetts,
USA) with the dsDNA HS Assay Kit (Table A1).
4.4.4. NGS
Libraries that passed the quality control check were pooled in equimolar ratios and
sequenced on a NextSeq500 instrument as a 75 bp read length (up to 46 bp insert + 19 bp 3′
linker + 10 bp UMIs) with an average depth of 22 million reads per sample.
4.4.5. Raw Data Processing
The workflow for miRNA sequencing data analysis, including trimming, alignment,
quantitation, normalisation and differential gene expression analysis is shown in Figure 15.
Figure 15. Key steps in the computational workflow for the analysis of miRNA sequencing data.
Raw data were de-multiplexed and FASTQ files were generated for each sample using
the bcl2fastq software (Illumina Inc., San Diego, CA, USA). FASTQ data were quality
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control checked using the FastQC tool and if identified, low-quality reads and artefacts
were removed. To correct PCR bias with UMI information, Cutadapt software (version 1.11)
was used to extract information on the adaptor presence and UMI raw reads. The output
was used to remove adapter sequences and to collapse reads by UMI. Briefly, reads were
processed by trimming off the 3′ adapter and low-quality bases. This was followed by
identification of insert sequences and UMI sequences. Reads with less than 16 bp insert
sequences (too short) or less than 10 bp UMI sequences (UMI defective) were discarded.
All reads containing identical insert sequence and UMI sequence combinations (insert-UMI
pair) were collapsed into a single read. The output of UMI correction included insert
sequences from collapsed full-UMI reads and reads which did not contain full length
UMI sequence (partial-UMI reads). These were then subjected to quality control checks
using FastQC to examine the overall sequence quality, the guanine-cytosine percentage
distribution and the presence of overrepresented sequences.
Reads that passed the above checks were then mapped using Bowtie 2 (2.2.2) as
follows: reads were first aligned to spike-ins (added at the RNA extraction stage, to
monitor extraction efficiency) and abundant sequences (outmapped reads, including polyA
and polyC homopolymers and abundant ribosomal or mitochondrial RNA sequences) were
filtered out. Perfect match to the reference sequence was required. The remaining reads
were then aligned to mature sequences of miRBase 20, with the requirement of a perfect
match. Unmapped reads were then aligned to the human reference genome, GRCh37, with
not more than one mismatch permitted in the first 32 bases of the read. Reads which aligned
to known miRNA loci in the genome were combined with the miRBase-mapped reads.
Reads that mapped to the reference genome outside the miRNA locus were classified as
novel miRNAs and were predicted using mirPara64 and miRbase. No indels were allowed
in any of the mapping steps.
To determine the miRNA call rate, after mapping the reads for a particular miRNA
were divided by the total number of mapped reads in the sample and then multiplied by
one million, denoted as TPM. For the purpose of differential expression analysis, raw reads
of the samples were normalised using Trimmed Mean of M values (TMM) normalisation
method using the EdgeR statistical software package (Bioconductor, http://bioconductor.
org/, accessed on 20 March 2021).
4.4.6. Differential Gene Expression Analysis
Differential expression analysis was performed using the EdgeR statistical software
package (Bioconductor, http://bioconductor.org/, accessed on 20 March 2021). To de-
termine dysregulated miRNAs associated with MNGIE, the TMM normalised miRNA
expression profiles of the disease samples were compared to the healthy control samples
(disease vs. healthy). A log2 Fold Change (logFC) in gene expression level with a change
cut-off of 1, representing the size of the change and a p-value with a false discovery rate
(FDR) correction cut off of < = 0.05 (Benjamini and Hochberg), representing the significance
of the change, were used to obtain the differentially expressed miRNAs [74]. Separate com-
parisons were also made between the following three disease and healthy age groups to
identify miRNAs that maybe associated with disease progression: ≤19, 20–29 and ≥30
years of age.
4.5. Downstream Bioinformatics Analyses
All downstream analyses were conducted in R Programming Language (R Core Team,
2016).
4.5.1. General Bioinformatics and QC
Unsupervised sample clustering was performed through the generation of dendro-
grams using Euclidean distance and Ward’s linkage, using the dist and hclust functions,
respectively. The distribution of samples was checked via box and whisker and violin plots
using ggplot2 [75]. QC was also gauged via pairwise scatterplot comparisons between
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control and MNGIE samples using the scatterplotMatrix function from the car package.
Linear regression, non-parametric gamma, and LOESS regression lines were fitted across
distributions and a histogram generated for each sample along the diagonal of the plot.
PCA was performed via the PCAtools package and volcano plots were generated via the
EnhancedVolcano package (https://github.com/kevinblighe/EnhancedVolcano, accessed
on 20 March 2021). Supervised clustering was performed by filtering genes/miRNAs
based on our threshold for statistical significance. Input data were converted to the Z
scale and then clustered via 1—Pearson correlation distance and Ward’s linkage using the
Heatmap function of the ComplexHeatmap package [76]. Box and whisker plots of miRNA
Z-scores were added to the heatmap diagram. Network plots and graphs were generated
via the igraph package [69]. Finally, box and whisker plots with scatter plot overlays were
produced via ggplot2.
4.5.2. Candidate Phase Micro RNA Signature
In the candidate phase, an initial miRNA signature (80 miRNAs) was identified by
taking those miRNAs that reached statistical significance from the following comparisons:
Disease group 1 vs. healthy group 1;
Disease group 2 vs. healthy group 2;
Disease group 3 vs. healthy group 3;
Disease vs. healthy.
To refine this signature, the identified miRNAs were used in a multinomial elastic-net
penalised regression model via glmnet [77]; this was cross-validated 10-fold and key miR-
NAs identified by taking those whose coefficients were not shrunk to zero. The resulting
refined panel (n = 41) was used in ROC analyses to derive the AUC. This initial signature
of 80 miRNAs (plus 10 further miRNAs of interest) was used to design a qPCR panel for
the validation phase.
4.5.3. Validation Phase
In the validation phase, fold-change comparisons were illustrated via ggplot2 [75],
comparing discovery vs. validation log2 fold-change values. A meta-analysed combined
p-value was calculated for each miRNA via the CombP function from GenRank in R;
this was performed separately for serum miRNA-seq/plasma qPCR and serum miRNA-
seq/serum qPCR. The meta-analysed p-value was then used to define a final panel of
miRNAs for the overall study. These final miRNAs were then further tested by regressing
each independently to the main end point (disease versus healthy) in a binary logistic
regression model. AUC was gauged by ROC analysis by plotting sensitivity against
specificity using the pROC package [78]. An area greater than 0.5 under the curve suggests
the utility of the miRNA in question in discriminating between healthy and disease.
4.5.4. MirRNA Gene Target Identification
In order to identify gene targets of each statistically significant miRNA, miRNAtap
was employed [79]. The following databases were selected for searching predicted gene
targets: DIANA, PicTar, TargetScan and miRanda [80–83]. The geometric mean score was
used for ranking each gene. A gene target for a particular miRNA was required to be
predicted in at least 2 of the 4 databases in order to be included. The final list of gene targets
was then visualised via the oncoPrint function of the ComplexHeatmap package [76].
4.5.5. Enrichment and Pathway Analysis
Target genes identified from miRNAtap were fed into topGO and KEGGprofile for
gene enrichment and pathway analysis, respectively [84,85]. The classic algorithm with the
Kolmogorov-Smirnov (K-S) test, which takes the rank of each target gene into consideration,
was used to determine statistically significantly enriched terms for each miRNA’s target
genes. For KEGG pathway enrichment, FDR adjusted p-values were used to determine
statistical significance.
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5. Conclusions
This study shows that five plasma and three serum miRNAs can discriminate MNGIE
disease from healthy controls and also the stage of disease. The signal in plasma appears
to be superior to that of serum, with the single best predictor of MNGIE being miR-34a-5p,
having an AUC of 0.977, and it was shown to be elevated across each age sub-group of
disease, when compared to any healthy group. A decrease in expression of miR-34a-5p
was noted during treatment with EE-TP in all four patients and coincided with clinical
biochemical and/or clinical improvements. Enrichment and pathway analysis identified a
number of candidate genes and networks that may play roles in MNGIE and are worthy
of further investigation. Although the dysregulation of these miRNAs is unlikely to be
specific to MNGIE compared to other mitochondrial diseases, the availability of an effective
and relatively non-invasive biomarker would meet an unmet need. The inclusion of the
exploratory plasma miRNA biomarker panel in future clinical trials of investigational
therapies for MNGIE would enable an appraisal of its prognostic value in assessing clinical
status.
Author Contributions: Conceptualisation, B.E.B.; methodology, M.M., M.L., B.E.B., software, K.B.;
formal analysis, M.M., K.B. and B.E.B.; investigation, M.M., M.L. and B.E.B.; resources, M.M., M.L.,
and B.E.B.; writing—original draft preparation and editing, M.M. and B.E.B.; writing—critical analy-
sis, K.B. and M.L.; supervision, B.E.B.; project administration, B.E.B. and M.L.; funding acquisition,
B.E.B. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by the Lily Foundation, reference LILY-2017.18 (APPLICATION
3—BAX) and the Medical Research Council, grant reference MR/K025406/1.
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki, and approved by the NHS Research Ethics Committee (London—Surrey
Borders, reference 18/LO/2173).
Data Availability Statement: The raw data are available from the corresponding author on reason-
able request.
Acknowledgments: The authors thank all study participants for providing blood samples. Project
group members included Rita Beier, Francisco J. Enguita, Massimiliano Filosto, Michio Hirano, Sema
Kalkan Uçar, Georg Kutschke, Hanna Mandel, Ramon Marti, Joanna Poulton, Agathe Roubertie,
Mauro Scarpelli, Se-bastian Schulz-Juergensen, Saba Tadesse, Galit Tal1, Javier Torres Torronteras
and Heinz Zoller.
Conflicts of Interest: M.H. served as a consultant and received research funding from Entrada
Therapeutics to assess their proprietary thymidine phosphorylase enzyme replacement therapy. The
funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in
the writing of the manuscript, or in the decision to publish the results.
Int. J. Mol. Sci. 2021, 22, 3681 36 of 50
Appendix A
Figure A1. Discovery study. Box and whisker plots showing the distributions of normalised miRNA expression for healthy control and MNGIE serum samples. No sample outliers were
identified.
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Table A1. Small RNA library concentration and quality control evaluation using a Qubit fluorimeter and Agilent 2100 Bioanalyzer with a DNA HighSensitivity chip.
Sample ID Qubit DNA Chip Correlation
Factor




SP1 0.352 3.1 156/183 0.21 1.68
SP2 8.16 72.6 168/181 6.22 1.31
SP3 6.04 53.7 164/180/185 5.21 1.16
SP4 6.7 59.6 166/180 5.89 1.14
SP5 6.4 56.9 165/186 6.24 1.03
SP7 12.2 108.5 185 9.69 1.26
SP8 7.42 66.0 170/190 5.31 1.40
SP11 7.46 66.3 168/190 4.49 1.66
SP13 6.7 59.6 168/183 5.63 1.19
SP14 3.72 33.1 172/182 2.84 1.31
SP15 8.28 73.6 184 6.33 1.31
SP16 4.72 42.0 184 3.56 1.33
SP17 6.24 55.5 171/184 4.48 1.39
SP19 6.62 58.9 167/181 4.51 1.47
SP22 6.46 57.4 170/179 5.27 1.23
SP24 7.14 63.5 165/180/185 5.59 1.28
SP25 3.46 30.8 165/185 2.91 1.19
SP26 6.06 53.9 168/186 5.28 1.15
SP28 13.8 122.7 182 11.8 1.17
SP29 4.22 37.5 171/180 3.2 1.32
SC1 6.54 58.2 171/180 4.8 1.36
SC2 5 44.5 171/183 3.71 1.35
SC3 4.46 39.7 167/181 3.8 1.17
SC4 4.4 39.1 167/180/185 3.62 1.22
SC5 7.12 63.3 168/179/188 5.39 1.32
SC7 5.9 52.5 171/181/187 5.46 1.08
SC8 4.78 42.5 172/181/189 3.78 1.26
SC11 5.12 45.5 181 4.29 1.19
SC13 5.22 46.4 181 4.57 1.14
SC14 4.62 41.1 182 3.98 1.16
SC15 8 71.1 170/182 6.36 1.26
SC16 5.06 45.0 172/184 3.49 1.45
SC17 6.96 61.9 169/183 5.03 1.38
SC19 6.02 53.5 184 6.02 1.00
SC22 6.52 58.0 173/184 4.82 1.35
SC24 5.58 49.6 185 4 1.40
SC25 8.1 72.0 170/186 6.13 1.32
SC26 11 97.8 184 8.23 1.34
SC28 9.42 83.8 184 6.77 1.39
SC29 6.88 61.2 167/181 5.94 1.16
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Figure A2. Expression of endogenous miRNAs. Top: miR-103, miR-23a, miR-30c, miR-451 and miR-142-3p expression levels in patient (SP) and healthy control (SC) serum samples were
consistent and within the expected range for biofluids. Bottom: The dCp (miR-23a–miR-451a) values were 5 or below, indicating that the samples were not affected by haemolysis.
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Table A2. Summary of mapping results of the reads by sample. Each sample consisted of reads that can be classified into the following categories: miRNA, smallRNA, predicted putative
miRNA, genome-mapped, outmapped or high abundance (e.g., rRNA, polyA, poly and, mtRNA) and unmapped (reads which did not align with the reference genome).
Sample Sample Group Raw Reads UMI-CorrectedReads miRNA Small RNA
Predicted
Putative Genome-Mapped Out-Mapped Unmapped
SP2 MNGIE 20,664,264 1,692,257 650,817 100,763 601 192,936 49,479 632,535
SP3 MNGIE 21,127,109 1,224,691 278,899 251,730 329 155,978 22,154 457,945
SP4 MNGIE 20,333,698 1,418,119 429,621 147,641 515 181,417 29,922 562,423
SP5 MNGIE 21,347,972 1,540,800 299,838 408,812 454 213,990 29,682 533,172
SP7 MNGIE 16,066,719 2,302,801 467,914 482,545 734 331,453 53,819 904,822
SP8 MNGIE 16,838,686 1,342,259 298,753 316,206 438 182,084 35,186 453,989
SP11 MNGIE 20,970,633 1,634,817 327,706 529,716 408 220,883 37,202 453,337
SP13 MNGIE 21,141,959 1,421,221 678,484 132,492 335 132,793 34,691 392,973
SP14 MNGIE 19,296,523 1,025,361 128,972 82,118 442 168,739 31,039 571,449
SP15 MNGIE 16,923,919 1,867,653 673,649 369,350 568 208,706 33,119 489,675
SP16 MNGIE 18,728,561 1,439,265 492,834 197,474 384 154,024 25,586 490,468
SP17 MNGIE 19,990,371 1,397,712 321,730 199,289 512 184,337 30,791 583,150
SP19 MNGIE 19,145,886 1,340,770 436,842 75,179 466 158,023 34,839 585,267
SP22 MNGIE 20,681,925 1,670,921 459,316 307,359 721 200,093 37,713 561,858
SP24 MNGIE 18,239,146 1,691,391 406,688 482,402 725 215,074 50,170 464,957
SP25 MNGIE 18,745,668 1,481,231 289,439 397,076 803 196,168 31,956 490,505
SP26 MNGIE 18,938,821 1,616,601 223,516 560,241 404 191,187 30,643 563,797
SP28 MNGIE 16,249,308 2,829,424 1,353,115 645,863 775 230,212 73,935 415,151
SP29 MNGIE 17,607,954 967,760 114,637 90,282 489 153,894 30,124 536,427
SC1 Control 20,047,242 1,425,635 246,775 223,325 749 204,667 205,037 499,649
SC2 Control 19,174,254 1,162,880 211,024 78,885 608 173,654 30,686 627,744
SC3 Control 19,572,619 1,165,596 254,498 180,714 475 156,400 32,348 485,578
SC4 Control 18,977,265 1,263,131 205,650 226,716 343 172,717 19,879 566,867
SC5 Control 19,111,231 1,330,492 199,993 274,267 710 195,275 62,165 549,749
SC7 Control 20,841,960 1,686,446 260,585 574,848 551 197,661 49,943 535,706
SC8 Control 19,707,934 1,300,028 80,815 296,634 491 210,555 41,962 623,245
SC11 Control 18,563,430 1,410,021 421,605 206,912 318 169,129 21,132 515,833
SC13 Control 20,066,962 1,708,975 330,017 281,688 1093 230,533 37,611 753,341
SC14 Control 19,274,934 1,445,280 449,689 192,179 533 180,822 29,709 525,387
SC15 Control 17,987,689 1,812,195 457,671 372,199 613 223,194 36,569 610,127
SC16 Control 18,510,527 1,368,296 326,311 211,476 486 193,179 25,249 545,638
SC17 Control 16,353,105 1,193,955 253,521 160,378 464 183,340 27,742 502,454
SC19 Control 19,108,362 1,566,082 398,520 214,029 520 199,157 28,460 632,067
SC22 Control 20,550,573 1,497,595 188,307 138,580 596 214,189 23,795 884,586
SC24 Control 20,375,566 1,462,403 492,804 196,533 404 184,880 28,799 483,227
SC25 Control 19,301,760 1,685,793 651,506 264,055 517 198,925 39,626 455,690
SC26 Control 18,149,356 2,402,158 1,036,238 474,154 540 237,515 48,912 484,333
SC28 Control 17,447,705 1,945,829 579,513 398,678 546 216,304 40,542 614,349
SC29 Control 18,520,877 1,632,676 550,777 200,806 737 218,689 34,023 551,392
Average 19,094,422 1,547,962 408,425 280,605 549 195,712 40,160 553,612
% age of UMI-corrected reads 26.4 18.1 0.0 12.6
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Figure A3. Average read quality of the Unique Molecular Index (UMI)-corrected reads for MNGIE patient samples (SP, left panel) and healthy control samples (SC, right panel). All
average Q-scores were above 30, indicating that the data were of high quality.
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Figure A4. Base quality of UMI-corrected reads for MNGIE patient samples (SP, left panel) and healthy control samples SC, (right panel). The red line is the mean Q-score and the blue line
is the median Q-score. The whiskers represent the 10% and 90% points. All average Q-scores were above 30 (>99.9% correct), indicating that the data were of high quality.
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Figure A5. Read length distribution of sequences obtained from 10,000 reads randomly selected from each control and MNGIE serum sample after removal of library and sequencing
adapters. miRNAs appear as a peak around 18–23 nucleotide bases (nt). The peak around 30 nt is likely to contain degraded RNA molecules (i.e., rRNA, tRNA and Y-RNA fragments).
Figure A6. Number of identified known miRNAs with number of counts being ≥1TPM per sample (dark blue bars) or ≥10 TPM per sample (light blue bars).
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Figure A7. Sample extraction efficiency and quality control. Top: RNA isolation (UniSp2 and UniSp4), cDNA synthesis (UniSp6) and qPCR efficiency controls. Middle: Sample miRNA
signals. miR-103, miR-30c and miR-23a are expressed at consistent levels in the majority of sample types. miR-142-3p is highly expressed in platelets and is an indicator of sample
contamination by this cell type. Bottom: The value of (miRNA23a–miRNA451a) provides an indicator of haemolysis: samples with a delta quantification cycle (dCq) value below 7 are
generally not affected by haemolysis.
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Figure A8. miRNA assay count and average Cq value for each sample. The blue bars represent the number of miRNAs assays detected and the red line shows the average Cq values for
the expressed miRNAs. On average, 64 miRNAs were detected per sample.
Figure A9. Box and whisker plots showing distribution of miRNA expression from each patient and healthy control plasma and serum sample after normalisation. The bottoms and tops
of the boxes represent the 25th and 75th percentiles, respectively, and the black bands are the 50th percentiles (the median). The whisker caps represent the minimum and maximum values.
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Table A3. Statistical output following binary logistic regression analyses of serum and plasma miRNAs that achieved meta-analyzed combined p-values < 0.0001.
Biofluid MicroRNA Beta Standard Error Z P Odds Ratio (OR) 95% Confidence Interval OR
Plasma
miR-34a-5p 8.11 3.46 2.34 0.0191 3334.32 28.27 58330583.76
miR-192-5p 2.37 0.85 2.80 0.0052 10.73 2.57 77.86
miR-193a-5p 3.48 1.22 2.85 0.0044 32.53 4.96 673.26
miR-194-5p 2.69 1.03 2.61 0.0090 14.75 2.87 183.24
miR-215-5p 3.58 1.16 3.09 0.0020 35.82 5.48 631.51
Serum
miR-34a-5p 1.74 0.68 2.58 0.0100 5.69 1.88 28.34
miR-192-5p 2.00 0.72 2.76 0.0057 7.41 2.21 39.76
miR-194-5p 1.51 0.61 2.47 0.0135 4.54 1.63 18.69
Table A4. The quantitative PCR microRNA panel employed in the validation and performance study phases.
Target RNA Notes Target RNA Target RNA Notes
hsa-let-7b-3p hsa-miR-203a-3p hsa-miR-4742-3p
hsa-let-7b-5p Normaliser hsa-miR-206 hsa-miR-483-3p
hsa-let-7i-5p Normaliser hsa-miR-210-3p hsa-miR-483-5p
hsa-miR-425-5p Normaliser hsa-miR-214-3p hsa-miR-484
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Table A4. Cont.








hsa-miR-194-5p hsa-miR-451a UniSp3 Spike-in control for PCR efficiency
hsa-miR-195-5p hsa-miR-455-5p UniSp6 Spike-in control for cDNA synthesisinhibition
hsa-miR-199a-5p hsa-miR-4732-5p
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